The Oncosearch | Oncotarget

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFÎºB signalling pathway Research Paper

Emma M. Smith, Lei Zhang, Brian A. Walker, Emma L. Davenport, Lauren I. Aronson, David Krige, Leon Hooftman, Alan H. Drummond, Gareth J. Morgan, Faith E. Davies

Published Aug 12, 2013 · Vol. 6, No. 19 · pp. 17314-17327

Keywords: Myeloma, HDAC inhibitor, aminopeptidase inhibitor, NFÎºB

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival Research Paper

Renji Reghunathan, Chonglei Bi, Shaw Cheng Liu, Koh Tze Loong, Tae-Hoon Chung, Gaofeng Huang, Wee Joo Chng

Published Jul 15, 2013 · Vol. 4, No. 8 · pp. 1230-1240

Keywords: : myeloma, plasma cells, proliferation, differentiation, stemness

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma Research Paper

Zhigang Xie, Jayantha Gunaratne, Lip Lee Cheong, Shaw Cheng Liu, Tze Loong Koh, Gaofeng Huang, Walter P Blackstock, Wee Joo Chng

Published Jun 26, 2013 · Vol. 4, No. 7 · pp. 1008-1018

Keywords: SILAC, quantitative proteomics, oncotargets, multiple myeloma

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism Research Paper

Brigitte Sola, Marc Poirot, Philippe de Medina, Sophie Bustany, VÃ©ronique Marsaud, Sandrine Sivente-Poirot, Jack-Michel Renoir

Published Jun 11, 2013 · Vol. 4, No. 6 · pp. 911-922

Keywords: multiple myeloma, tamoxifen, autophagy, apoptosis, cholesterol metabolism

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma Research Paper

Maria Teresa Di Martino, Annamaria GullÃ, Maria Eugenia Gallo Cantafio, Marta Lionetti, Emanuela Leone, Nicola Amodio, Pietro Hiram Guzzi, Umberto Foresta, Francesco Conforti, Mario Cannataro, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri, Pierfrancesco Tassone

Published Feb 24, 2013 · Vol. 4, No. 2 · pp. 242-255

Keywords: miR-221, miR-222, microRNA, miRNA, multiple myeloma, plasma cell leukemia

PU.1 is a tumor suppressor for B cell malignancies Editorial

Yutaka Okuno, Hiromichi Yuki

Published Dec 31, 2012 · Vol. 3, No. 12 · pp. 1495-1496

Keywords: PU.1, classical Hodgkin lymphoma, multiple myeloma, cell cycle arrest, apoptosis, p21, TRAIL

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia Review

Virginie Chesnais, Olivier Kosmider, Frederik Damm, Raphael Itzykson, Olivier A Bernard, Eric Solary, Michaela Fontenay

Published Nov 30, 2012 · Vol. 3, No. 11 · pp. 1284-1293

Keywords: splicing, alternative splicing, mutations, myeloid malignancies

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Research Paper

Anouk Caraux, Laure Vincent, Salahedine Bouhya, Philippe Quittet, JÃ©rÃ´me Moreaux, Guilhem Requirand, Jean-Luc Veyrune, GaÃ«lle Olivier, Guillaume Cartron, Jean-FranÃ§ois Rossi, Bernard Klein

Published Oct 25, 2012 · Vol. 3, No. 11 · pp. 1335-1347

Keywords: Multiple Myeloma, Plasma cells, Minimal residual disease, Human

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma Research Paper

Nicola Amodio, Marzia Leotta, Dina Bellizzi, Maria Teresa Di Martino, Patrizia D'Aquila, Marta Lionetti, Fernanda Fabiani, Emanuela Leone, Anna Maria GullÃ, Giuseppe Passarino, Michele Caraglia, Massimo Negrini, Antonino Neri, Antonio Giordano, Pierosandro Tagliaferri, Pierfrancesco Tassone

Published Oct 21, 2012 · Vol. 3, No. 10 · pp. 1246-1258

Keywords: miRNA, miR-29b, multiple myeloma, DNMT

Second Primary Malignancies and Myeloma Therapy: Fad or Fact? Editorial

Saad Z Usmani

Published Sep 15, 2012 · Vol. 3, No. 9 · pp. 915-916

Brutonâ€™s tyrosine kinase: oncotarget in myeloma Editorial

Yu-Tzu Tai, Kenneth C. Anderson

Published Sep 12, 2012 · Vol. 3, No. 9 · pp. 913-914

Keywords: Brutonâ€™s tyrosine kinase, multiple myeloma, bone marrow microenvironment, osteoclast, osteoblast

Oncogene addiction to c-MYC in myeloma cells Editorial

Toril Holien, Anders Sundan

Published Aug 25, 2012 · Vol. 3, No. 8 · pp. 739-740

Keywords: MYC, myeloma, oncogene

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy Research Paper

Dipankar Pramanik, Nathaniel R Campbell, Samarjit Das, Sonal Gupta, Venugopal Chenna, Savita Bisht, Polina Sysa-shah, Djahida Bedja, Collins Karikari, Charles Steenbergen, Kathleen L. Gabrielson, Amarnath Maitra, Anirban Maitra

Published Jul 10, 2012 · Vol. 3, No. 6 · pp. 640-650

Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing Methodological Reports

Renee C. Tschumper, Yan W. Asmann, Asif Hossain, Paul M. Huddleston, Xiaosheng Wu, Angela Dispenzieri, Bruce W. Eckloff, Diane F. Jelinek

Published Apr 20, 2012 · Vol. 3, No. 4 · pp. 502-513

Keywords: IGHV, multiple myeloma, massively parallel sequencing

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib Research Paper

Nickolay Neznanov, Andrei P. Komarov, Lubov Neznanova, Patricia Stanhope-Baker, Andrei V. Gudkov

Published Mar 27, 2011 · Vol. 2, No. 3 · pp. 209-221

Keywords: bortezomib, puromycin, hyperthermia, heat shock, apoptosis, cancer treatment, translation, ubiquitination, protein degradation, protein denaturing

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance Research Paper

Lei Shi, Siqing Wang, Maurizio Zangari, Hongwei Xu, Thai M. Cao, Chunjiao Xu, Yong Wu, Fang Xiao, Yinghong Liu, Ye Yang, Mohamed Salama, Guiyuan Li, Guido Tricot, Fenghuang Zhan

Published May 15, 2010 · Vol. 1, No. 1 · pp. 22-33

A critical role for the NFkB pathway in multiple myeloma Research Perspective

Yulia N. Demchenko, W. Michael Kuehl

Published May 1, 2010 · Vol. 1, No. 1 · pp. 59-68

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFÎºB signalling pathway Research Paper

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival Research Paper

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma Research Paper

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism Research Paper

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma Research Paper

PU.1 is a tumor suppressor for B cell malignancies Editorial

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia Review

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Research Paper

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma Research Paper

Second Primary Malignancies and Myeloma Therapy: Fad or Fact? Editorial

Brutonâ€™s tyrosine kinase: oncotarget in myeloma Editorial

Oncogene addiction to c-MYC in myeloma cells Editorial

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy Research Paper

Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing Methodological Reports

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib Research Paper

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance Research Paper

A critical role for the NFkB pathway in multiple myeloma Research Perspective

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFÎºB signalling pathway Research Paper

Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival Research Paper

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma Research Paper

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism Research Paper

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma Research Paper

PU.1 is a tumor suppressor for B cell malignancies Editorial

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia Review

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Research Paper

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma Research Paper

Second Primary Malignancies and Myeloma Therapy: Fad or Fact? Editorial

Brutonâ€™s tyrosine kinase: oncotarget in myeloma Editorial

Oncogene addiction to c-MYC in myeloma cells Editorial

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy Research Paper

Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-D-J Intraclonal Variation Using Massively Parallel Pyrosequencing Methodological Reports

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib Research Paper

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance Research Paper

A critical role for the NFkB pathway in multiple myeloma Research Perspective